Guay D R
Drug Intell Clin Pharm. 1983 Feb;17(2):83-91. doi: 10.1177/106002808301700201.
Netilmicin sulfate, the 1-N-ethyl derivative of sisomicin, is a new aminoglycoside recently released for use in Canada and not yet released in the U.S. Its place in therapeutics, compared with gentamicin (G), tobramycin (T), and amikacin (A), is not yet established. Preliminary work in animals has suggested a lower incidence of nephrotoxicity and ototoxicity than with other aminoglycosides, and in vitro work has suggested some activity against G/T-resistant organisms. However, netilmicin appears to be virtually identical to G,T, and A in antimicrobial spectrum (except for its poorer activity against P. aeruginosa), human toxicity, and clinical use. For G/T-resistant organisms, amikacin is still the aminoglycoside of choice. In summary, netilmicin has not been demonstrated to have significant advantages over other aminoglycosides (G,T,A), and it is more expensive; thus, its potential value is limited.
硫酸奈替米星是西索米星的1-N-乙基衍生物，是一种新的氨基糖苷类药物，最近在加拿大获准使用，在美国尚未获批。与庆大霉素（G）、妥布霉素（T）和阿米卡星（A）相比，其在治疗中的地位尚未确立。动物实验初步结果表明，与其他氨基糖苷类药物相比，其肾毒性和耳毒性发生率较低，体外实验表明其对G/T耐药菌有一定活性。然而，奈替米星在抗菌谱（除对铜绿假单胞菌活性较差外）、人体毒性和临床应用方面似乎与G、T和A几乎相同。对于G/T耐药菌，阿米卡星仍是首选的氨基糖苷类药物。总之，奈替米星并未显示出比其他氨基糖苷类药物（G、T、A）有显著优势，且价格更贵；因此，其潜在价值有限。
